Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00373347 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Identification of New Serum Diagnostic Markers of Hepatocellular Carcinoma

StatusCompleted
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Completed Enrollment target: estimated 600 to confirmed 573 · Primary and study completion dates changed from estimate of Dec 2025 to Nov 18, 2024 · Site details revisedv25 Show all 4 changesShow less
    • Enrollment target: estimated 600 to confirmed 573
    • Primary and study completion dates changed from estimate of Dec 2025 to Nov 18, 2024
    • Site details revised
  2. Enrollment target: 300 to 600v24
  3. 2 versions Re-verified since Jan 25, 2023, no change to tracked fieldsv22-v23
  4. Primary completion date: Dec 2021 to Dec 2025v21
  5. Primary completion date: Dec 2020 to Dec 2021 Primary endpoint revised · Eligibility criteria expanded, about 2 wordsv20 Show all 3 changesShow less
    • Primary endpoint revised
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

Show 18 earlier versionsHide 18 earlier versions
  1. Re-verified, no change to tracked fieldsv19
  2. Study Status, Eligibilityv18
  3. 2 versions Re-verified since Apr 21, 2016, no change to tracked fieldsv16-v17
  4. Primary completion date: Dec 2014 to Dec 2020 Completion date: Dec 2018 to Dec 2025v15 Show all 2 changesShow less
    • Completion date: Dec 2018 to Dec 2025
  5. Study Status, Study Description, Outcome Measuresv14
  6. Re-verified, no change to tracked fieldsv13
  7. Primary completion date: Dec 2012 to Dec 2014 Completion date: Dec 2014 to Dec 2018v12 Show all 2 changesShow less
    • Completion date: Dec 2014 to Dec 2018
  8. 4 versions Re-verified since Jun 14, 2010, no change to tracked fieldsv8-v11
  9. Primary completion date: Dec 2012 Completion date: Dec 2014 · Eligibility criteria revisedv7 Show all 3 changesShow less
    • Completion date: Dec 2014
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  10. Eligibility criteria revisedv6 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  11. Eligibility criteria shortened, about 1 wordv5 Show moreShow less

    See this version in full on ClinicalTrials.gov ↗

  12. Study site revised Eligibility criteria shortened, about 1 wordv4 Show all 2 changesShow less
    • Eligibility criteria shortened, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  13. 2 versions Re-verified since Feb 8, 2007, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Stanford University
633 trials monitored
See 46 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
The purpose of this study is to identify blood markers that have the ability to diagnose liver cancer with improved accuracy, so that it can be used alone or in conjunction with alpha-feto protein (AFP)
Trial Details
NCT Number NCT00373347
Lead Sponsor Stanford University
Conditions Liver Cancer
Enrollment 573 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov